Company Overview and News

 
Developments sites under the spotlight

6h theage.com.au
Investors and developers are circling two significant sites from Sydney's west to the northern beaches with an eye to constructing tourism assets and boosting exposure in residential freeholds.
WBC WBC WEBNF WBK

 
Developments sites under the spotlight

6h watoday.com.au
Investors and developers are circling two significant sites from Sydney's west to the northern beaches with an eye to constructing tourism assets and boosting exposure in residential freeholds.
WBC WBC WEBNF WBK

 
Developments sites under the spotlight

6h smh.com.au
Investors and developers are circling two significant sites from Sydney's west to the northern beaches with an eye to constructing tourism assets and boosting exposure in residential freeholds.
WBC WBC WEBNF WBK

 
National Australia Bank cuts 300 staff over wrongdoing

16h channelnewsasia
SYDNEY: About 300 staff of National Australia Bank have been fired or left the company as a result of internal investigations into wrongdoing, Chief Executive Andrew Thorburn said on Friday (Oct 19), following public revelations of misconduct across the sector.
NAUBF WBC WBC NAB NASXF WEBNF NABZY WBK

 
Australia's NAB cuts 300 staff over wrongdoing

16h reuters
SYDNEY (Reuters) - About 300 staff of National Australia Bank (NAB.AX) have been fired or left the company as a result of internal investigations into wrongdoing, Chief Executive Andrew Thorburn said on Friday, following public revelations of misconduct across the sector.
NAUBF WBC WBC NAB NASXF WEBNF NABZY WBK

 
Australia's NAB cuts 300 bankers over wrongdoing

18h reuters
SYDNEY (Reuters) - About 300 staff of National Australia Bank (NAB.AX) have been fired or left the company as a result of internal investigations into wrongdoing, Chief Executive Andrew Thorburn said on Friday, following public revelations of misconduct across the sector.
NAUBF WBC WBC NAB NASXF WEBNF NABZY WBK

 
Net migration falls as growing number of migrants pack their bags

18h nzherald.co.nz
New Zealand's annual net migration continued to fall from record levels last year as a growing number of migrants pack their bags and leave.
WBC WBC WEBNF WBK

 
US data drags oil lower, US dollar up after Fed minutes

2018-10-17 malaymail
NEW YORK, Oct 18 — Oil prices fell yesterday after US crude inventories rose by much more than expected and exports fell, while the US dollar added to gains after minutes showed Federal Reserve policy makers largely united on the need to raise borrowing costs further.
WBC WBC WEBNF WBK

 
U.S. data drags oil lower; dollar up after Fed minutes

2018-10-17 theedgemarkets
NEW YORK (Oct 18): Oil prices fell on Wednesday after U.S. crude inventories rose by much more than expected and exports fell, while the dollar added to gains after minutes showed Federal Reserve policy makers largely united on the need to raise borrowing costs further.
WBC WBC WEBNF WBK

 
U.S. data drags oil lower; dollar up after Fed minutes

2018-10-17 reuters
NEW YORK (Reuters) - U.S. oil prices tumbled and Brent also fell on Wednesday after crude inventories rose by much more than expected and exports fell, while the dollar added to gains after minutes showed Federal Reserve policymakers generally agreed borrowing costs were set to rise further.
WBC WBC WEBNF WBK

13
31 'Safer' Dividend Financial WallStars For October From Dividend Dogcatcher

2018-10-15 seekingalpha
WallStars are distinguished by positive broker target price upsides. Top 10 Financial Services 'safer' dividend WallStars, MC, MFC, LM, DGICA, APO, WBK, IVZ, LAZ, and BGCP averaged 33.89% upsides 10/10/18.
AIY BGCP AINV APO APAM AB TCRX WBC ARCC GBDC BGCA LMHA WEBNF AIB WBK TCRD LMHB TCRZ TSLF OCSI ARU MFC 0945 WBC LAZ MFC DGICA DGICB LM IVZ

4
Financial Services WallStars Sight 23%-46% Broker Targets For October 2019

2018-10-14 seekingalpha
WallStars are distinguished by positive broker target price upsides. Five top net-gain financial services WallStars, GARS, WBK, OFS, CMFN, & TCRD averaged 34.67% estimated net gains (per 1yr. targets) 10/10/18.
AIY CMFN TCRX WBC AINV GARS FDUS WHFBL WEBNF MRCC TCPC BVA AIB WBK TCRD TCRZ WHF TSLF WBC OFS

3
New Strong Sell Stocks for October 12th

2018-10-12 zacks - 3
U.S. Silica Holdings, Inc. (SLCA - Free Report) is a seller of commercial silica in the United States.The Zacks Consensus Estimate for its current year earnings has been revised 1.2% downward over the last 30 days.
ATU WBC WBC EMES WEBNF WBK SLCA

 
Australia's ANZ fired 200 staff due to bad banking behaviour — CEO

2018-10-12 theedgemarkets
SYDNEY (Oct 12): Australia and New Zealand Banking Group fired over 200 staff for wrongdoing, including senior executives, due in part to issues raised at a public inquiry into financial sector misconduct, ANZ Chief Executive Shayne Elliott said on Friday.
WBC WBC WEBNF WBK

 
Australia#39;s ANZ fired 200 staff due to bad banking behaviour: CEO Elliott

2018-10-12 moneycontrol
Australia and New Zealand Banking Group fired over 200 staff for wrongdoing, including senior executives, due in part to issues raised at a public inquiry into financial sector misconduct, ANZ Chief Executive Shayne Elliott said on Friday.
WBC WBC WEBNF WBK

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: AA6076142